AXON rides on demand for TASER 10, Axon Body 4 and counter-drone tech as Connected Devices growth accelerates.
Axon Enterprise offers a compelling long-term growth story, with founder-led vision, high retention rates, and expanding recurring revenue streams. Recent Q3 earnings miss and tariff-driven margin compression triggered a selloff, but I view this as a buying opportunity for growth-oriented investors. AXON's TAM of $159B, international expansion, and AI-driven Axon 911 platform, supported by strategic M&A, underpin robust future growth prospects.
Axon (AXON) reported earnings 30 days ago. What's next for the stock?
AXON's 31% slide contrasts with strong device and software growth as rising costs, debt and valuation cloud near-term sentiment.
Axon Enterprise (AXON) shares have dropped by 26.6% within a month, falling from $732.23 on October 31, 2025, to $537.75 currently. What lies ahead?
AXON's rising margins, fueled by strong TASER and platform sales, support an upgraded 2025 EBITDA outlook despite cost pressures.
Axon adapted its business model to become a winner. The company continues to evolve, painting an optimistic picture of the future.
Axon's surging Software & Services revenues and stronger 2025 outlook spotlight rising demand for digital evidence tools and premium features.
Axon (AXON) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
The broader market has surged to record highs in 2025, with the S&P 500 up about 14% year-to-date.
Axon's Connected Devices segment surges on strong TASER 10 and Body 4 demand, driving 24% revenue growth.
Axon (AXON) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.